Document Detail


The emergency use of recombinant hirudin in cardiopulmonary bypass.
MedLine Citation:
PMID:  10915479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The most common anticoagulant used for cardiopulmonary bypass is heparin. An alternate form of anticoagulant therapy is needed for patients who have immune-mediated heparin-associated thrombocytopenia (HIT). Thrombocytopenia causes bleeding and may lead to serious arterial and venous thrombosis. HIT or heparin-induced thrombocytopenia with thrombosis type II (HITT) are both described as adverse reactions to heparin. They are diagnosed with a platelet count less than a 100,000/mcl for 2 consecutive days. HITT, the severe form, is characterized with the thrombocytopenia in combination with thromboembolic complications, such as strokes, myocardial infarctions, and limb ischemia. Two cases are presented in which r-hirudin was used for anticoagulation for aortocoronary bypass surgery and mitral valve replacement. The activated partial prothrombin time (aPTT) was used to monitor coagulation. In the first case, the aPTT was maintained greater than 100 seconds, and at the termination of cardiopulmonary bypass, some clot was noted in the cardiopulmonary bypass circuit. In the second case, a longer cardiopulmonary bypass run was anticipated, the hirudin bolus and infusion rate were increased, and the aPTT was maintained at greater than 200 sec. Adequate coagulation resulted, and, at the end of bypass, no clot was noted. These case studies seem to suggest a higher dosage of r-hirudin may be required for the use of cardiopulmonary bypass and a need to maintain aPTT values greater than 200 sec to help monitor anticoagulation.
Authors:
N Johnston; M E Jessen; M DiMaio; D S Douglass
Related Documents :
3272209 - Anticoagulation variability between centres: implications for comparative prosthetic va...
11771609 - R-hirudin as anticoagulant for cardiopulmonary bypass.
12730559 - Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of...
16327259 - Anticoagulation in ischemic stroke: opportunities in arterial disease.
19159859 - Superselective embolization of renal hemorrhage occurring after percutaneous coronary i...
11693739 - Role of transesophageal echocardiography-guided cardioversion of patients with atrial f...
8602559 - Development of st-segment elevation and q- and r- wave changes in acute myocardial infa...
10755209 - Verapamil in acute myocardial infarction. the rationales of the vami and davit iii trials.
11593219 - Usefulness of distinct activity thresholds according to baseline regional asynergy for ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Journal of extra-corporeal technology     Volume:  31     ISSN:  0022-1058     ISO Abbreviation:  J Extra Corpor Technol     Publication Date:  1999 Dec 
Date Detail:
Created Date:  2000-06-09     Completed Date:  2000-06-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0267637     Medline TA:  J Extra Corpor Technol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  211-5     Citation Subset:  T    
Affiliation:
Division of Thoracic and Cardiovascular Surgery, University of Texas Southwestern Medical Center at Dallas 75235-88679, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use*
Cardiopulmonary Bypass* / adverse effects
Drug Administration Schedule
Hirudin Therapy*
Humans
Male
Middle Aged
Recombinant Proteins / therapeutic use*
Thrombocytopenia / blood,  prevention & control*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Systemic inflammation induced by cardiopulmonary bypass: a review of pathogenesis and treatment.
Next Document:  Surface modification of stents for improving biocompatibility.